Outcome of Board Meeting held today i.e. November 14, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Eraaya Lifespaces' board met on November 14, 2025 and flagged three key items. First, unaudited financial results for Q2 and H1 FY26 (ended September 30, 2025) were NOT approved and have been deferred to the next board meeting because of the need to verify 'certain transactions, valuations, and business reorganizations within subsidiaries.' Second, the board approved a preferential allotment of 28,60,412 equity shares at Rs. 40.64 per share (face value Re. 1, premium Rs. 39.64) to two non-promoter allottees — Melanie Lane Partners Series Fund LLP (16,50,172 shares) and Watch Hill Capital (12,10,240 shares) — who are existing shareholders of its US subsidiary Ebix Inc., in lieu of their Ebix shareholding and 'certain other obligations.' After this, Eraaya will hold 100% of Ebix Inc., eliminating the minority interest. Third, an EGM has been scheduled for December 9, 2025 to seek shareholder approval for the preferential issue.
The deferral of Q2/H1 results amid an ongoing subsidiary review is a clear red flag for investors and could weigh on the stock until clarity emerges. The preferential swap helps clean up the corporate structure by removing Ebix minority interest, but the underlying reason — verification needs around a historically distressed US subsidiary — raises concerns about hidden liabilities or valuation issues that existing shareholders should monitor closely ahead of the December 9 EGM.